Sergio Traversa - Jan 29, 2024 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Executive Officer, Director
Signature
/s/ Sergio Traversa
Stock symbol
RLMD
Transactions as of
Jan 29, 2024
Transactions value $
$386,738
Form type
4
Date filed
1/31/2024, 06:29 PM
Previous filing
Dec 19, 2023
Next filing
May 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $117K +31.5K +21.9% $3.71 176K Jan 29, 2024 Direct F1, F2
transaction RLMD Common Stock Purchase $160K +41K +23.35% $3.90 217K Jan 30, 2024 Direct F1, F3
transaction RLMD Common Stock Purchase $110K +27.5K +12.68% $4.00 244K Jan 31, 2024 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2 Purchase prices range from $3.69 to $3.75 per share, inclusive.
F3 Purchase prices range from $3.88 to $3.97 per share, inclusive.
F4 Purchase prices range from $3.95 to $4.05 per share, inclusive.